Filing Flows › Arcutis Biotherapeutics (ARQT) › Q2 2026 › vs Q1 2026
Arcutis Biotherapeutics (ARQT) Q2 2026 vs Q1 2026 (quarter over quarter)
Arcutis Biotherapeutics's revenue rose $24.5M (+23%) from $105M in Q1 2026 to $130M in Q2 2026. The biggest changes: ZORYVE foam +$17.8M (+36%); ZORYVE cream 0.3% +$2.7M (+8%); ZORYVE cream 0.15% +$2.5M (+11%). Operating margin 12.7% against -8.6% (+21.3 pts).
Arcutis Biotherapeutics, Q2 2026: revenue $130M (+59% year over year), operating margin 12.7%, net earnings $15.0M, operating cash flow $12.6M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Operating margin | 12.7% | -8.6% | +21.3 pts |
| Net margin | 11.6% | -10.7% | +22.3 pts |
| Free cash flow margin | 9.6% | 2.1% | +7.5 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| ZORYVE foam | $67.4M | $49.6M | $17.8M | +36% |
| ZORYVE cream 0.3% | $35.3M | $32.7M | $2.7M | +8% |
| ZORYVE cream 0.15% | $24.2M | $21.7M | $2.5M | +11% |
| ZORYVE cream 0.05% | $2.9M | $1.4M | $1.6M | +115% |
| Revenue | $130M | $105M | $24.5M | +23% |
| Operating profit | $16.4M | −$9.1M | $25.5M | — |
| Costs & expenses | $113M | $114M | −$1.1M | -0.9% |
| Pre-tax earnings | $15.1M | −$11.2M | $26.3M | — |
| Other expense, net | $1.3M | $2.1M | −$829K | -39% |
| Cost of revenue | $10.9M | $9.8M | $1.2M | +12% |
| Research & development | $20.4M | $30.6M | −$10.3M | -34% |
| SG&A | $82.1M | $74.1M | $8.1M | +11% |
| Net earnings | $15.0M | −$11.3M | $26.3M | — |
| Income tax | $136K | $93K | $43K | +46% |
| Operating cash sources | $27.8M | −$605K | $28.4M | — |
| Share-based compensation | $12.8M | $10.7M | $2.1M | +19% |
| Working capital & other | $15.1M | −$2.8M | $18.0M | — |
| Operating cash flow | $12.6M | $2.2M | $10.4M | +464% |
| Free cash flow (OCF − capex) | $12.5M | $2.2M | $10.2M | +457% |
| Capital expenditures | $158K | $0 | $158K | — |
Questions
How much did Arcutis Biotherapeutics's revenue grow quarter over quarter in Q2 2026?
Arcutis Biotherapeutics's revenue rose $24.5M (+23%) from $105M in Q1 2026 to $130M in Q2 2026.
What drove Arcutis Biotherapeutics's revenue change in Q2 2026?
ZORYVE foam +$17.8M (+36%); ZORYVE cream 0.3% +$2.7M (+8%); ZORYVE cream 0.15% +$2.5M (+11%).